GNH USA

Europe — EMA

Megalotect Cp

GNH USA supplies Megalotect Cp (Human Cytomegalovirus Immunoglobulin), an immunoglobulin for preventing CMV infection in transplant recipients and treating

Human Cytomegalovirus Immunoglobulin

Request sourcing

1
Pack/s

What is Human Cytomegalovirus Immunoglobulin?

Human Cytomegalovirus Immunoglobulin, the active ingredient in Megalotect Cp, is an immunoglobulin presented as an injectable solution for intravenous use. It provides passive immunity to prevent or treat cytomegalovirus infection in transplant recipients and immunocompromised patients, helping to reduce disease severity and transmission risk.

GNH USA supplies Megalotect Cp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

What is Human Cytomegalovirus Immunoglobulin used for?

Megalotect Cp is an immunoglobulin that targets cytomegalovirus infection in high‑risk patient groups. - Prevention of cytomegalovirus infection in transplant recipients: reduces the incidence of primary CMV disease after organ transplantation. - Treatment of CMV disease in immunocompromised patients: assists in controlling active infection in individuals with weakened immune systems. - Prophylaxis in hematopoietic stem cell transplantation: provides passive immunity during the high‑risk post‑transplant period.

What are the side effects of Human Cytomegalovirus Immunoglobulin?

Adverse reactions may occur with any immunoglobulin infusion. Monitoring during and after administration is recommended.

Common Side Effects: - Fever - Chills - Headache - Nausea - Mild infusion‑related reactions (e.g., erythema, itching) - Transient hypertension

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Thromboembolic events - Renal dysfunction or acute kidney injury - Aseptic meningitis - Hemolysis - Severe hypotension

What precautions apply to Human Cytomegalovirus Immunoglobulin?

Use of Megalotect Cp requires careful clinical assessment and monitoring. - Assess CMV serostatus: confirm indication based on donor/recipient serology. - Monitor for infusion reactions: observe patients during and after infusion. - Avoid in patients with known severe IgA deficiency: risk of anaphylaxis. - Use with caution in renal impairment: adjust volume and monitor renal function. - Pregnancy: safety not established; weigh potential benefits against unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Human Cytomegalovirus Immunoglobulin interact with?

Megalotect Cp may interact with other therapies; awareness of potential interactions helps ensure safe use.

Major Interactions (Avoid): - Concurrent administration with other immunoglobulin products: may increase hyperviscosity risk. - Live vaccines: may diminish vaccine efficacy. - Anticoagulants: volume load may potentiate bleeding risk.

Moderate Interactions (Monitor Closely): - Corticosteroids: may alter immune response to CMV. - Renally toxic drugs: monitor renal function closely. - Cytotoxic chemotherapy: watch for additive immunosuppression.

Frequently asked questions

What is Megalotect Cp used for?+
Megalotect Cp is used to prevent cytomegalovirus (CMV) infection in organ transplant recipients and to treat active CMV disease in patients with compromised immune systems, such as those undergoing hematopoietic stem cell transplantation or receiving intensive immunosuppressive therapy.
How does Human Cytomegalovirus Immunoglobulin work?+
The immunoglobulin provides passive immunity by delivering high‑titer antibodies that specifically bind to CMV particles. These antibodies neutralize the virus, block its entry into host cells, and promote clearance by the recipient’s immune system, thereby limiting viral replication and disease.
What is the usual dose of Megalotect Cp?+
The dosing regimen for Megalotect Cp is individualized and determined by the prescribing clinician based on factors such as the patient’s weight, CMV serostatus, type of transplant, and clinical condition. Exact dosage and infusion rate should follow the prescriber’s instructions and local guidelines.
Is Megalotect Cp safe during pregnancy or breastfeeding?+
Safety data for Megalotect Cp in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing individuals.
How do I order Megalotect Cp from GNH USA?+
To order Megalotect Cp, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.
How does Megalotect Cp compare with other CMV therapies?+
Megalotect Cp offers passive immunization, whereas antiviral agents such as valganciclovir provide active viral suppression. Immunoglobulin therapy can be advantageous for prophylaxis or when antiviral resistance is a concern, but it requires intravenous administration and careful monitoring for infusion‑related reactions.
What are the storage and handling requirements for Megalotect Cp?+
Megalotect Cp must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required by the infusion protocol.
How is Megalotect Cp administered?+
Megalotect Cp is administered as an intravenous infusion. The infusion rate and total volume are determined by the prescriber, often starting slowly to assess tolerance and then increasing as needed. Administration should occur under medical supervision with facilities to manage potential infusion reactions.
What are the most serious risks to watch for with Megalotect Cp?+
The most serious risks include severe allergic reactions such as anaphylaxis, thromboembolic events, acute renal dysfunction, aseptic meningitis, and hemolysis. Immediate medical attention is required if any signs of these reactions appear during or after infusion.
Who should not use Megalotect Cp?+
Megalotect Cp should be avoided in patients with a known severe IgA deficiency, a history of anaphylactic reactions to immunoglobulin products, or those who have demonstrated hypersensitivity to any component of the formulation. Clinicians should also exercise caution in patients with uncontrolled renal impairment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Human Cytomegalovirus Immunoglobulin
Route
Intravenous Use
Manufacturer
Biotest Pharma Gmbh
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU